Komori
Ono Pharmaceutical (4528) · FactGreater full-year contribution from Deciphera products

Sales growth of key new products other than Opdivo

First written in FY2019-Q3. . Latest entry: FY2026.

27entries
8years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2019-Q3 – FY20262019: 420192020: 420202021: 420212022: 420222023: 420232024: 320242025: 220252026: 22026
Same theme, other companies
Expanding revenue from core products and strengthening the product portfolioA theme 5 companies write about · 0 as a headwind · 7 as a tailwind

0 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026Greater full-year contribution from Deciphera productsAnnual report

    「Revenue from Qinlock, a treatment for gastrointestinal stromal tumors sold by Deciphera, increased by ¥12.9 billion, or 50.6%, from the previous consolidated fiscal year to ¥38.4 billion; the previous consolidated fiscal year included revenue for 9 months from July to March. Revenue from Romvimza, a treatment for tenosynovial giant cell tumor (TGCT), was ¥8.3 billion.」

    Deciphera products made a larger full-year contribution, with Qinlock generating ¥38.4 billion and Romvimza ¥8.3 billion in revenue.
  2. 2026-05-21OtherGeneral Meetings of Shareholders

    「Sales of Qinlock, a treatment for gastrointestinal stromal tumors, sold by Deciphera Pharmaceuticals (meaning Deciphera Pharmaceuticals, Inc. in the United States, its subsidiaries or the Deciphera Pharmaceuticals group as a whole), increased by ¥12.9 billion, or 50.6%, year on year to ¥38.4 billion (the previous fiscal year included nine months of sales, from July to March), while sales of Romvimza, a treatment for tenosynovial giant cell tumor (TGCT), amounted to ¥8.3 billion.」

    Products from Deciphera Pharmaceuticals contributed to higher overseas product sales, demonstrating their role as a new source of revenue.
  3. FY2026-H1Mixed performance among major products in the interim period, with a contribution from Deciphera productsAnnual report

    「Revenue from Qinlock, a treatment for gastrointestinal stromal tumors sold by Deciphera, increased by ¥10.0 billion, or 123.3%, year on year to ¥18.1 billion; the prior-year figure represented revenue for 3 months from July to September. Revenue from Qinlock was ¥18.1 billion. Revenue from Romvimza, a treatment for tenosynovial giant cell tumor (TGCT), was ¥2.8 billion. Among the other major products, Orencia subcutaneous injection, for rheumatoid arthritis, generated ¥13.8 billion, up 2.1% year on year; Glactiv tablets, for type 2 diabetes, generated ¥6.9 billion, down 28.2%; Bexicle tablets, an antineoplastic agent, generated ¥6.0 billion, up 15.8%; Ongentys tablets, for Parkinson's disease, generated ¥4.5 billion, up 18.6%; Parsabiv intravenous dialysis injection, for secondary hyperparathyroidism in patients undergoing hemodialysis, generated ¥4.5 billion, up 7.4%; and Kyprolis intravenous infusion, for multiple myeloma, generated ¥4.0 billion, down 12.1%.」

    While Qinlock and Romvimza contributed revenue as Deciphera products, the other major products showed mixed revenue performance.
  4. FY2025Mixed performance among major products for the full year, with a contribution from Deciphera productsAnnual report

    「Revenue from Qinlock, a treatment for gastrointestinal stromal tumors sold by Deciphera, amounted to ¥25.5 billion for the 9 months from July to March. ... Among the other major products, Orencia subcutaneous injection, for rheumatoid arthritis, generated ¥26.6 billion, up 3.0% from the previous consolidated fiscal year; Glactiv tablets, for type 2 diabetes, generated ¥18.3 billion, down 13.4%; Bexicle tablets, an antineoplastic agent, generated ¥10.5 billion, up 3.1%; Kyprolis intravenous infusion, for multiple myeloma, generated ¥8.6 billion, down 5.9%; Parsabiv intravenous dialysis injection, for secondary hyperparathyroidism in patients undergoing hemodialysis, generated ¥8.4 billion, up 2.5%; and Ongentys tablets, for Parkinson's disease, generated ¥7.6 billion, up 21.0%.」

    While the major products showed mixed performance, Qinlock from Deciphera recorded ¥25.5 billion in revenue during the 9 months following the acquisition, adding a new source of revenue to the product portfolio.
  5. FY2025-H1Mixed performance among major products in the interim periodAnnual report

    「Among the other major products, Orencia subcutaneous injection, for rheumatoid arthritis, generated ¥13.5 billion, up 3.5% year on year; Glactiv tablets, for type 2 diabetes, generated ¥9.6 billion, down 11.2%; Bexicle tablets, an antineoplastic agent, generated ¥5.2 billion, up 3.7%; Kyprolis intravenous infusion, for multiple myeloma, generated ¥4.6 billion, down 1.0%; Parsabiv intravenous dialysis injection, for secondary hyperparathyroidism in patients undergoing hemodialysis, generated ¥4.2 billion, up 0.7%; and Ongentys tablets, for Parkinson's disease, generated ¥3.8 billion, up 21.4%.」

    While Orencia, Bexicle, Parsabiv and Ongentys generated higher revenue, Glactiv and Kyprolis generated lower revenue, resulting in divergent sales trends among the major products.
  6. FY2024Mixed performance among major new products for the full yearAnnual report

    「Among the other major new products, Orencia subcutaneous injection, for rheumatoid arthritis, generated ¥25.8 billion, up 4.3% from the previous consolidated fiscal year; Glactiv tablets, for type 2 diabetes, generated ¥21.2 billion, down 5.9%; Bexicle tablets, an antineoplastic agent, generated ¥10.2 billion, up 19.7%; Kyprolis intravenous infusion, for multiple myeloma, generated ¥9.1 billion, up 5.1%; Parsabiv intravenous dialysis injection, for secondary hyperparathyroidism in patients undergoing hemodialysis, generated ¥8.2 billion, down 2.1%; and Ongentys tablets, for Parkinson's disease, generated ¥6.3 billion, up 26.8%.」

    For the full year, Orencia, Bexicle, Kyprolis and Ongentys generated higher revenue, while Glactiv and Parsabiv generated lower revenue, and differences between products continued.
  7. FY2024-Q3Mixed performance among major new products in the third quarterAnnual report

    「Among the other major new products, Forxiga tablets, indicated for diabetes, chronic heart failure and chronic kidney disease, generated ¥57.5 billion, up 37.3% year on year; Orencia subcutaneous injection, for rheumatoid arthritis, generated ¥20.0 billion, up 4.8%; Glactiv tablets, for type 2 diabetes, generated ¥16.7 billion, down 5.3%; Bexicle tablets, an antineoplastic agent, generated ¥8.0 billion, up 22.0%; Kyprolis intravenous infusion, for multiple myeloma, generated ¥7.1 billion, up 4.8%; Parsabiv intravenous dialysis injection, for secondary hyperparathyroidism in patients undergoing hemodialysis, generated ¥6.4 billion, down 2.0%; and Ongentys tablets, for Parkinson's disease, generated ¥4.9 billion, up 27.0%.」

    For the nine months ended the third quarter, Forxiga, Orencia, Bexicle, Kyprolis and Ongentys generated higher revenue, while Glactiv and Parsabiv generated lower revenue, with differences between the major new products continuing. Forxiga generated ¥57.5 billion, up 37.3% year on year.
  8. FY2024-Q2Forxiga and others generated higher revenue in the first half, with differences between products continuingAnnual report

    「Among the other major new products, Forxiga tablets, indicated for diabetes, chronic heart failure and chronic kidney disease, generated ¥35.9 billion, up 36.1% year on year; Orencia subcutaneous injection, for rheumatoid arthritis, generated ¥13.0 billion, up 4.5%; Glactiv tablets, for type 2 diabetes, generated ¥10.8 billion, down 7.5%; Bexicle tablets, an antineoplastic agent, generated ¥5.0 billion, up 22.0%; Kyprolis intravenous infusion, for multiple myeloma, generated ¥4.6 billion, up 3.9%; Parsabiv intravenous dialysis injection, for secondary hyperparathyroidism in patients undergoing hemodialysis, generated ¥4.1 billion, down 2.9%; and Ongentys tablets, for Parkinson's disease, generated ¥3.1 billion, up 27.9%.」

    While Forxiga, Orencia, Bexicle, Kyprolis and Ongentys generated higher revenue, Glactiv and Parsabiv generated lower revenue, with differences between the major new products continuing.
  9. FY2024-Q1Mixed performance among major new products in the first quarterAnnual report

    「Among the other major new products, Forxiga tablets for diabetes, chronic heart failure and chronic kidney disease generated ¥17.5 billion (up 34.0% year on year), Orencia subcutaneous injection for rheumatoid arthritis generated ¥6.6 billion (up 5.6%), Glactiv tablets for type 2 diabetes generated ¥5.6 billion (down 7.2%), Belexible tablets, an anticancer drug, generated ¥2.6 billion (up 23.7%), Kyprolis intravenous infusion for multiple myeloma generated ¥2.2 billion (down 0.1%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥2.1 billion (down 3.0%), and Ongentys tablets for Parkinson's disease generated ¥1.6 billion (up 28.8%).」

    While Forxiga, Orencia, Bexicle and Ongentys generated higher revenue, Glactiv, Kyprolis and Parsabiv generated lower revenue, with differences between the major new products continuing.
  10. FY2023Mixed performance among major new products for the full yearAnnual report

    「Among the other major new products, Forxiga tablets for diabetes, chronic heart failure and chronic kidney disease generated ¥56.5 billion (up 54.3% from the previous fiscal year), Orencia subcutaneous injection for rheumatoid arthritis generated ¥24.8 billion (up 8.1%), and Glactiv tablets for type 2 diabetes generated ¥22.5 billion (down 8.3%).」

    Forxiga, Orencia and other products generated higher full-year revenue, while Glactiv, Parsabiv and other products generated lower revenue, with differences by product among major new products continuing.
  11. FY2023-Q3Mixed performance among major new products in the third quarterAnnual report

    「Among the other major new products, Forxiga tablets for diabetes, chronic heart failure and chronic kidney disease generated ¥41.9 billion (up 58.0% year on year), Orencia subcutaneous injection for rheumatoid arthritis generated ¥19.1 billion (up 9.0%), Glactiv tablets for type 2 diabetes generated ¥17.7 billion (down 8.5%), Kyprolis intravenous infusion for multiple myeloma generated ¥6.8 billion (up 4.4%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥6.5 billion (down 5.6%), Belexible tablets, an anticancer drug, generated ¥6.5 billion (up 38.5%), and Ongentys tablets for Parkinson's disease generated ¥3.8 billion (up 91.8%).」

    For the nine months ended the third quarter, Forxiga, Orencia, Kyprolis, Belexible and Ongentys generated higher revenue, while Glactiv and Parsabiv generated lower revenue, resulting in differences in sales trends among major new products.
  12. FY2023-Q2Mixed performance among major new products in the first halfAnnual report

    「Among the other major new products, Forxiga tablets for diabetes, chronic heart failure and chronic kidney disease generated ¥26.4 billion (up 68.8% year on year), Orencia subcutaneous injection for rheumatoid arthritis generated ¥12.5 billion (up 11.0%), Glactiv tablets for type 2 diabetes generated ¥11.7 billion (down 8.0%), Kyprolis intravenous infusion for multiple myeloma generated ¥4.4 billion (up 6.5%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥4.3 billion (down 5.3%), Belexible tablets, an anticancer drug, generated ¥4.1 billion (up 43.4%), and Ongentys tablets for Parkinson's disease generated ¥2.4 billion.」

    For the six months ended the second quarter, Forxiga, Orencia, Kyprolis, Belexible and other products generated higher revenue, while Glactiv and Parsabiv generated lower revenue, resulting in differences in sales trends among major new products.
  13. FY2023-Q1Mixed performance among major new products in the first quarterAnnual report

    「Among the other major new products, Forxiga tablets for diabetes, chronic heart failure and chronic kidney disease generated ¥13.1 billion (up 75.3% year on year), Orencia subcutaneous injection for rheumatoid arthritis generated ¥6.2 billion (up 9.4%), Glactiv tablets for type 2 diabetes generated ¥6.0 billion (down 6.7%), Kyprolis intravenous infusion for multiple myeloma generated ¥2.2 billion (up 12.6%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥2.1 billion (down 3.1%), Belexible tablets, an anticancer drug, generated ¥2.1 billion (up 45.1%), and Ongentys tablets for Parkinson's disease generated ¥1.2 billion.」

    In the first quarter of the fiscal year ending March 2023, Forxiga, Orencia, Kyprolis, Belexible and other products generated higher revenue, while Glactiv and Parsabiv generated lower revenue, resulting in differences in sales trends among major new products.
  14. FY2022Full-year growth in Forxiga and other major new products continued, with differences by productAnnual report

    「Among the other major new products, Forxiga tablets for diabetes, chronic heart failure and chronic kidney disease generated ¥36.7 billion (up 64.0% from the previous fiscal year), Glactiv tablets for type 2 diabetes generated ¥24.5 billion (down 3.8%), Orencia subcutaneous injection for rheumatoid arthritis generated ¥22.9 billion (up 4.5%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥8.9 billion (up 10.2%), and Kyprolis intravenous infusion for multiple myeloma generated ¥8.4 billion (up 17.5%).」

    Forxiga, Orencia, Parsabiv and Kyprolis generated higher revenue, while Glactiv generated lower revenue, and differences in sales among major new products continued.
  15. FY2022-Q3Growth in major new products and differences by product continued in the third quarterAnnual report

    「Among the other major new products, Forxiga tablets for diabetes, chronic heart failure and chronic kidney disease generated ¥26.5 billion (up 59.9% year on year), Glactiv tablets for type 2 diabetes generated ¥19.3 billion (down 2.9%), Orencia subcutaneous injection for rheumatoid arthritis generated ¥17.5 billion (up 4.4%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥6.9 billion (up 10.1%), and Kyprolis intravenous infusion for multiple myeloma generated ¥6.5 billion (up 19.8%).」

    For the nine months ended the third quarter, Forxiga, Orencia, Parsabiv and Kyprolis generated higher revenue, while Glactiv generated lower revenue. Forxiga continued to expand sales as a product covering chronic kidney disease.
  16. FY2022-Q2First-half growth in major new products and expanded indicationsAnnual report

    「Forxiga tablets for diabetes, chronic heart failure and chronic kidney disease generated ¥15.6 billion (up 49.3% year on year), Glactiv tablets for type 2 diabetes generated ¥12.7 billion (down 1.7%), Orencia subcutaneous injection for rheumatoid arthritis generated ¥11.2 billion (up 3.3%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥4.5 billion (up 15.6%), and Kyprolis intravenous infusion for multiple myeloma generated ¥4.2 billion (up 18.6%).」

    Forxiga, Orencia, Parsabiv and Kyprolis generated higher first-half revenue, while Glactiv generated lower revenue. Forxiga also received approval for an additional indication for chronic kidney disease.
  17. FY2022-Q1Growth in major new products and new product launchesAnnual report

    「Among the other major new products, Forxiga tablets for diabetes and chronic heart failure generated ¥7.5 billion (up 43.3% year on year), Glactiv tablets for type 2 diabetes generated ¥6.5 billion (down 1.1%), Orencia subcutaneous injection for rheumatoid arthritis generated ¥5.7 billion (up 4.5%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥2.2 billion (up 15.3%), and Kyprolis intravenous infusion for multiple myeloma generated ¥2.0 billion (up 18.9%). Edolsmiz tablets for cancer cachexia were newly launched in April 2021, and Joyclu intra-articular injection for improving joint function was newly launched in May 2021.」

    Forxiga, Orencia, Parsabiv and Kyprolis generated higher revenue, while Glactiv generated lower revenue. Edolsmiz tablets and Joyclu intra-articular injection were also newly launched.
  18. FY2021Full-year growth in major new products, with differences by productAnnual report

    「Among the other major new products, Glactiv tablets for type 2 diabetes generated ¥25.5 billion (down 2.1% from the previous fiscal year), Forxiga tablets for diabetes and chronic heart failure generated ¥22.4 billion (up 23.7%), Orencia subcutaneous injection for rheumatoid arthritis generated ¥21.9 billion (up 10.4%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥8.1 billion (up 13.9%), and Kyprolis intravenous infusion for multiple myeloma generated ¥7.1 billion (up 18.8%).」

    For the full year, Forxiga, Orencia, Parsabiv and Kyprolis generated higher revenue, while Glactiv generated lower revenue, with differences in sales trends among major new products continuing.
  19. FY2021-Q3Growth in major new products and differences by product continued in the third quarterAnnual report

    「Among the other major new products, Glactiv tablets for type 2 diabetes generated ¥19.9 billion (down 3.2% year on year), Orencia subcutaneous injection for rheumatoid arthritis generated ¥16.8 billion (up 10.5%), Forxiga tablets for diabetes and chronic heart failure generated ¥16.6 billion (up 20.3%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥6.3 billion (up 14.9%), and Kyprolis intravenous infusion for multiple myeloma generated ¥5.4 billion (up 17.3%).」

    Orencia, Forxiga, Parsabiv and Kyprolis generated higher revenue, while Glactiv generated lower revenue, with differences by product among major new products continuing.
  20. FY2021-Q2First-half growth in major new products, with differences by productAnnual report

    「Among the other major new products, Glactiv tablets for type 2 diabetes generated ¥13.0 billion (down 2.3% year on year), Orencia subcutaneous injection for rheumatoid arthritis generated ¥10.9 billion (up 8.9%), Forxiga tablets for diabetes generated ¥10.5 billion (up 20.5%), Rivastach patches for Alzheimer's disease generated ¥4.1 billion (down 7.0%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥3.9 billion (up 11.9%), and Kyprolis intravenous infusion for multiple myeloma generated ¥3.5 billion (up 19.8%).」

    Orencia, Forxiga, Parsabiv and Kyprolis generated higher revenue, while Glactiv and Rivastach generated lower revenue, with differences by product continuing among major new products.
  21. FY2021-Q1First-quarter growth in major new products, with differences by productAnnual report

    「Among the other major new products, Glactiv tablets for type 2 diabetes generated ¥6.5 billion (down 5.9% year on year), Orencia subcutaneous injection for rheumatoid arthritis generated ¥5.4 billion (up 10.6%), Forxiga tablets for diabetes generated ¥5.2 billion (up 17.8%), Rivastach patches for Alzheimer's disease generated ¥2.0 billion (down 10.0%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥1.9 billion (up 11.1%), and Kyprolis intravenous infusion for multiple myeloma generated ¥1.7 billion (up 21.3%).」

    Orencia, Forxiga, Parsabiv and Kyprolis generated higher revenue, while Glactiv and Rivastach generated lower revenue, with differences by product continuing among major new products.
  22. FY2020Full-year growth in major new products, with differences by productAnnual report

    「Among the other major new products, Glactiv tablets for type 2 diabetes generated ¥26.1 billion (down 3.1% from the previous fiscal year), Orencia subcutaneous injection for rheumatoid arthritis generated ¥19.8 billion (up 13.8%), Forxiga tablets for diabetes generated ¥18.1 billion (up 24.7%), Emend capsules and Proemend intravenous infusion for nausea and vomiting associated with anticancer treatment generated ¥10.7 billion in total (up 1.0%), Rivastach patches for Alzheimer's disease generated ¥8.5 billion (down 4.2%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥7.1 billion (up 23.6%), and Kyprolis intravenous infusion for multiple myeloma generated ¥6.0 billion (up 21.9%).」

    For the full year, Orencia, Forxiga, Emend/Proemend, Parsabiv and Kyprolis generated higher revenue, while Glactiv and Rivastach generated lower revenue.
  23. FY2020-Q3Growth in major new products and differences by product continued in the third quarterAnnual report

    「Among the other major new products, Glactiv tablets for type 2 diabetes generated ¥20.5 billion (down 3.0% from the nine months ended the third quarter of the previous fiscal year), Orencia subcutaneous injection for rheumatoid arthritis generated ¥15.2 billion (up 13.1%), Forxiga tablets for diabetes generated ¥13.8 billion (up 24.5%), Emend capsules and Proemend intravenous infusion for nausea and vomiting associated with anticancer treatment generated ¥8.9 billion in total (up 7.9%), Rivastach patches for Alzheimer's disease generated ¥6.7 billion (down 4.0%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥5.5 billion (up 23.7%), and Kyprolis intravenous infusion for multiple myeloma generated ¥4.6 billion (up 18.0%).」

    Orencia, Forxiga, Emend/Proemend, Parsabiv and Kyprolis generated higher revenue, while Glactiv and Rivastach generated lower revenue, with differences by product continuing among major new products.
  24. FY2020-Q2Broad-based growth among major new products, with differences by productAnnual report

    「Among the other major new products, Glactiv tablets for type 2 diabetes generated ¥13.3 billion (down 3.3% from the six months ended the second quarter of the previous fiscal year), Orencia subcutaneous injection for rheumatoid arthritis generated ¥10.0 billion (up 16.0%), Forxiga tablets for diabetes generated ¥8.7 billion (up 24.4%), Emend capsules and Proemend intravenous infusion for nausea and vomiting associated with anticancer treatment generated ¥5.9 billion in total (up 10.4%), Rivastach patches for Alzheimer's disease generated ¥4.4 billion (down 3.7%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥3.5 billion (up 28.4%), and Kyprolis intravenous infusion for multiple myeloma generated ¥2.9 billion (up 13.5%).」

    Orencia, Forxiga, Emend/Proemend, Parsabiv and Kyprolis generated higher revenue, while Glactiv and Rivastach generated lower revenue, indicating differences in sales trends among major new products.
  25. FY2020-Q1Mixed performance among major new productsAnnual report

    「Among the other major new products, Glactiv tablets for type 2 diabetes generated ¥6.9 billion (down 2.1% from the first-quarter cumulative period of the previous fiscal year), Orencia subcutaneous injection for rheumatoid arthritis generated ¥4.9 billion (up 13.6%), Forxiga tablets for diabetes generated ¥4.4 billion (up 22.5%), Emend capsules and Proemend intravenous infusion for nausea and vomiting associated with anticancer treatment generated ¥2.9 billion in total (up 8.8%), Rivastach patches for Alzheimer's disease generated ¥2.3 billion (down 2.0%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥1.7 billion (up 33.2%), and Kyprolis intravenous infusion for multiple myeloma generated ¥1.4 billion (up 3.1%).」

    Orencia, Forxiga, Emend/Proemend, Parsabiv and Kyprolis generated higher revenue, while Glactiv and Rivastach generated lower revenue, indicating differences in sales trends among major new products.
  26. FY2019Full-year sales growth, with differences by productAnnual report

    「Among the other major new products, Glactiv tablets for type 2 diabetes generated ¥26.9 billion (down 1.8% from the previous fiscal year), Orencia subcutaneous injection for rheumatoid arthritis generated ¥17.4 billion (up 23.3%), Forxiga tablets for type 2 diabetes generated ¥14.5 billion (up 31.0%), Emend capsules and Proemend intravenous infusion for nausea and vomiting associated with anticancer treatment generated ¥10.6 billion in total (up 6.6%), Rivastach patches for Alzheimer's disease generated ¥8.9 billion (up 0.2%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥5.7 billion (up 66.8%), and Kyprolis intravenous infusion for multiple myeloma generated ¥4.9 billion (down 11.1%).」

    Excluding Opdivo, Orencia, Forxiga, Emend/Proemend, Rivastach and Parsabiv generated higher full-year revenue, while Glactiv and Kyprolis generated lower revenue.
  27. FY2019-Q3First statedAnnual report

    「Among the other major new products, Glactiv tablets for type 2 diabetes generated ¥21.2 billion (down 5.2% from the nine months ended the third quarter of the previous fiscal year), Orencia subcutaneous injection for rheumatoid arthritis generated ¥13.4 billion (up 23.5%), Forxiga tablets for type 2 diabetes generated ¥11.1 billion (up 30.6%), Emend capsules and Proemend intravenous infusion for nausea and vomiting associated with anticancer treatment generated ¥8.2 billion in total (up 5.8%), Rivastach patches for Alzheimer's disease generated ¥7.0 billion (down 0.4%), Parsabiv intravenous dialysis formulation for secondary hyperparathyroidism in hemodialysis patients generated ¥4.4 billion (up 77.6%), and Kyprolis intravenous infusion for multiple myeloma generated ¥3.9 billion (down 12.7%).」

    Several major new products, including Orencia, Forxiga, Emend/Proemend and Parsabiv, generated higher revenue year on year, while Glactiv, Rivastach and Kyprolis generated lower revenue.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Ono Pharmaceutical's next results are scheduled for 2026-10-29. Read the earnings preview It last moved in the General Meetings of Shareholders of 2026-05-21: "Other".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Sales growth of key new products other than Opdivo | ONO PHARMACEUTICAL CO.,LTD. (4528) | Komori